Peripherally acting µ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy

Joseph V. Pergolizzi, Robert B. Raffa, Marco Pappagallo, Charles Fleischer, Joseph Pergolizzi, Gianpietro Zampogna, Elizabeth Duval, Janan Hishmeh, Jo Ann LeQuang, Robert Taylor

Research output: Contribution to journalReview articlepeer-review

Abstract

Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting µ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting µ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.

Original languageEnglish (US)
Pages (from-to)107-119
Number of pages13
JournalPatient Preference and Adherence
Volume11
DOIs
StatePublished - 2017

Keywords

  • Noncancer pain patients
  • Opioid bowel disorder
  • Opioid-associated side effects
  • Opioid-induced constipation
  • PAMORA
  • Peripherally acting mu-opioid receptor antagonist

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Social Sciences (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Fingerprint Dive into the research topics of 'Peripherally acting µ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy'. Together they form a unique fingerprint.

Cite this